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immune genes, histone modifiers and chromatin
remodeling factors within 5 years after birth in
human blood leukocytes
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Riitta Veijola6, Olli Simell7, Jorma Toppari8, Jorma Ilonen9, Mikael Knip10,11,13, Annika Scheynius1, Heikki Hyöty5,12,
Dario Greco4 and Juha Kere2,13*Abstract
Background: Age-related changes in DNA methylation occurring in blood leukocytes during early childhood may
reflect epigenetic maturation. We hypothesized that some of these changes involve gene networks of critical
relevance in leukocyte biology and conducted a prospective study to elucidate the dynamics of DNA methylation.
Serial blood samples were collected at 3, 6, 12, 24, 36, 48 and 60 months after birth in ten healthy girls born in
Finland and participating in the Type 1 Diabetes Prediction and Prevention Study. DNA methylation was measured
using the HumanMethylation450 BeadChip.
Results: After filtering for the presence of polymorphisms and cell-lineage-specific signatures, 794 CpG sites
showed significant DNA methylation differences as a function of age in all children (41.6% age-methylated and
58.4% age-demethylated, Bonferroni-corrected P value <0.01). Age-methylated CpGs were more frequently
located in gene bodies and within +5 to +50 kilobases (kb) of transcription start sites (TSS) and enriched in
developmental, neuronal and plasma membrane genes. Age-demethylated CpGs were associated to promoters
and DNAse-I hypersensitivity sites, located within −5 to +5 kb of the nearest TSS and enriched in genes related
to immunity, antigen presentation, the polycomb-group protein complex and cytoplasm.
Conclusions: This study reveals that susceptibility loci for complex inflammatory diseases (for example, IRF5,
NOD2, and PTGER4) and genes encoding histone modifiers and chromatin remodeling factors (for example,
HDAC4, KDM2A, KDM2B, JARID2, ARID3A, and SMARCD3) undergo DNA methylation changes in leukocytes during
early childhood. These results open new perspectives to understand leukocyte maturation and provide a
catalogue of CpG sites that may need to be corrected for age effects when performing DNA methylation
studies in children.
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Methylation of cytosines to 5-methylcytosines in the con-
text of CpG dinucleotides is an important epigenetic modi-
fication that regulates gene expression and cell-specific
functions. Some DNA methylation signatures are main-
tained during mitosis and contribute to the so-called ‘epi-
genetic memory’, which determine cell lineage. Other DNA
methylation patterns are very dynamic, change during life-
time and mediate several physiological events such as cell
differentiation, cell maturation and tissue-specific gene ex-
pression [1,2]. From early developmental stages through
senescence, CpG sites are methylated by DNA methyl-
transferases (DNMT3a/DNMT3b and DNMT1) [3] and
demethylated either passively or by active mechanisms
implicating 5-hydroxymethylation, ten-eleven translocator
(TET) proteins and thymidine glycosidases [4,5]. Studies
in diverse human tissues have demonstrated that DNA
methylation levels are modified as a function of age [6-10].
Indeed, it is possible to predict the age of a tissue based on
its methylation signatures on a broad number of CpG sites
[6,9,11-13]. Most studies investigating age-associated DNA
methylation changes have been performed in adults and
from the perspective of cell senescence, longevity, cancer,
stem cell functions and chronological age [12,14-19]. Still,
few studies have documented the dynamics of DNA
methylation during early childhood [20-23].
It is known that increasing age leads to genome-wide de-
methylation in transposable repetitive elements (including
Alu and L1) as well as in gene coding regions [19,24,25]. In-
creasing age is also associated to increased methylation of
certain CpGs in specific gene families, CpG islands [26],
polycomb (PcG) target genes [27] and promoters with bi-
valent chromatin domains [28]. Age-associated changes in
DNA methylation have been implicated in tumour develop-
ment and certain chronic diseases [29]. The recognition of
age-modified CpG sites in infants is essential to identify
genes that might be epigenetically modified during this
period of life and, if disturbed, might contribute to the sus-
ceptibility to complex inflammatory diseases in childhood.
The identification of age-modified CpG sites during early
childhood is also important, because early exposure to en-
vironmental factors such as pollutants and pesticides might
alter the methylation levels of inflammatory genes and these
signatures may be sustained during years, possibly predis-
posing to disease [30,31]. The aims of this study were the
following: 1) to identify CpG sites with longitudinal changes
in DNA methylation levels within 3 to 60 months after
birth in healthy children and 2) to annotate the genomic
distribution and functional relationships of age-modified
CpG sites during early childhood. The present study pro-
vides a catalogue of 794 age-modified CpG sites that ro-
bustly reflect the changes in DNA methylation levels that
occur in human blood leukocytes within 3 to 60 months
after birth. Notably, we found that the genomic location ofage-modified CpG sites differs depending whether the
CpGs become age methylated or age demethylated. The
functional annotation of the genes containing age-modified
loci indicated that methylation changes related to age may
not be due only to a stochastic DNA methylation drift but
rather correspond to a programme with potential functional
relevance in leukocyte biology during this period of life.
Results
We analysed the longitudinal changes in DNA methy-
lation in a total of 60 samples at 3, 6, 12, 24, 36, 48
and 60 months after birth, using serial DNA samples
extracted from peripheral blood leukocytes of ten
healthy girls participating in the Finnish Type 1 Dia-
betes Prediction and Prevention Study (DIPP) (Table 1).
DNA methylation levels were measured in 485.577
CpG sites distributed in 99% of the annotated RefSeq genes
using the HumanMethylation450 BeadChip (Illumina, San
Diego, CA, USA) [32]. DNA methylation levels were log2
transformed to M values and then statistically evaluated
using limma [33]. A single procedure consisting of two
steps was used to infer the association between age and
DNA methylation. In the first step, a linear model was used
considering the age and the individual (repeated samples
from the same person); the study of the variance was per-
formed but no list of differentially methylated probes was
generated. Then, the information on the variance was uti-
lized as prior for the second step of the analysis, which
consisted of a moderated t-test carried out comparing the
DNA methylation in samples at 3 months vs the samples
at 60 months. We found 853 CpG sites with significant dif-
ferential methylation due to age (Bonferroni-corrected P
value <0.01). Of these, 476 CpGs were exclusively affected
by age and 377 CpGs were affected by both age and indi-
vidual (Figure 1A). Since single nucleotide polymorphisms
(SNPs) in the probe sequence may affect methylation mea-
surements, all age-modified CpG sites containing a SNP
within the probe with a minor allele frequency (MAF)
above 0.01 in the Finnish population were filtered out
(n = 48). Moreover, to avoid the confounding effects of
CpG sites that are differentially methylated among
leukocyte populations due to cell lineage (cell specific), the
853 age-modified CpG sites were contrasted against a list
of 2,228 CpG sites with significant differential DNA methy-
lation in sorted leukocytes [34], which serve as cell-type
classifiers. Eleven age-modified CpG sites were found in
this list and therefore excluded. After these filtering steps,
794 age-modified CpG sites remained for further analyses
(330 age-methylated sites and 464 age-demethylated sites)
(Figure 1B). The detailed list of age-modified CpG sites and
fold changes of M values and P values is found in Additional
file 1.
Age-modified CpG sites were found in all autosomes
with frequencies that correlated with the distribution of
Table 1 Descriptive information on the study individuals (n = 10)
Child
number
Date of
birth
HLA-DR-DQ
haplotype
Risk
classa
Mode of
delivery
Maternal
smoking
during
pregnancy
Age at end of
exclusive
breast-feeding
(months)
Age at end
of total
breast-feeding
(months)
Samples (time
points) included
in the analysis
after QC
1 2000.03.21 DRB1*04:01-DQB1*03:02/
DRB1*04:04-DQB1*03:02
3 Caesarean
section
No - <3 3 m, 12 m, 24 m, 36 m,
48 m, 60 m
2 2000.04.10 DRB1*04:04-DQB1*03:02/
(DR1/10)-DQB1*05:01
3 Caesarean
section
No 2.2 3.5 24 m, 60 m
3 2002.04.18 DRB1*04:04-DQB1*03:02/
(DR1/10)-DQB1*05:01
3 Vaginal No <5 7 to 11 3 m, 6 m, 12 m, 24 m,
48 m, 60 m
4 2002.05.16 DRB1*04:04-DQB1*03:02/
(DR7)-DQA1*02:01-DQB1*03:03
1 Vaginal Yes 0.2 10.5 3 m, 6 m, 12 m, 24 m,
48 m, 60 m
5 2002.08.04 DRB1*04:01-DQB1*03:02/
DRB1*04:04-DQB1*03:02
3 Vaginal No 5.0 10.0 3 m, 6 m, 12 m, 24 m,
36 m, 48 m, 60 m
6 2002.08.21 DRB1*04:04-DQB1*03:02/
(DR9)-DQA1:03-DQB1*03:03
3 Vaginal No <3 13 to 17 3 m, 12 m, 24 m, 48 m,
60 m
7 2002.10.04 DRB1*04:01-DQB1*03:02/
(DR8)-DQB1*04
3 Vaginal No 3.0 8.0 3 m, 6 m, 12 m, 24 m,
36 m, 48 m, 60 m
8 2002.10.29 DRB1*04:01-DQB1*03:02/
(DR1/10)-DQB1*05:01
3 Caesarean
section
No <3 8 to 11 3 m, 6 m, 12 m, 24 m,
36 m, 48 m, 60 m
9 2002.11.20 DRB1*04:03-DQB1*03:02/
(DR13)-DQB1*06:03
0 Vaginal No 5.5 9.0 3 m, 6 m, 12 m, 24 m,
36 m, 48 m, 60 m
10 2002.11.21 DRB1*04:04-DQB1*03:02/
(DR1/10)-DQB1*05:01
3 Vaginal No 2.0 2.7 3 m, 6 m, 12 m, 24 m,
36 m, 48 m, 60 m
aRisk for T1D classified in five classes from decreased risk (0) to strongly increased risk (4) as presented in Hekkala et al [50].
HLA = human leukocyte antigen; m =months.
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for the X chromosome which had only one age-modified
CpG site in the 5′UTR of the gene encoding claudin 2 (chrX:
106161451, pbonf = 3.34 × 10
−9). Considering that this
chromosome contains 11,232 of all tested probes (2.3%),
our finding reproduces previous observations suggesting
that the X chromosome is ‘reluctant’ to methylation changes
over time [20,22]. Furthermore, age-modified CpG sites
were most frequently located in RNA coding genes than in
intergenic regions. There were no deviations from the ex-
pected proportions according to the distribution of probes
in the 450 K assay between age-methylated and age-
demethylated sites (Figure 1D).
The effects of age on the DNA methylation levels of these
sites were supported by the identification of genes having at
least two age-modified CpG sites (range two to six sites)
spanning over stretches of sequence from few base pairs
(bp) up to kilobases (mean 19.7 ± 51.1 kb). If at least two
CpG sites showed the same methylation trend in a given
loci, they configure an age-modified region. Nowadays, the
length of a differentially methylated region or the number
of CpG sites that they should contain is debated; therefore
in the present study, we adopted this more global definition
to consider a broader sequence length and the tendency of
the age effects. Genes containing age-methylated regions
are presented in Table 2, and genes containing age-
demethylated regions are presented in Table 3. Further sup-
port on these findings was suggested by the detection ofage-modified CpG sites in genes belonging to the same
families but encoded on separate chromosomes, for in-
stance the homeobox cluster A on chromosome
7p15.2 (HOXA3 and HOXA10) and the homeobox
cluster B on chromosome 17q21.3 (HOXB6) (Additional
files 1 and 2).
Since age-modified CpG sites were detected in whole
blood, we further investigated their cell-type specific an-
notations according to the Illumina manifest. First, none
of the 794 age-modified CpG sites was annotated to
known tissue-specific differentially methylated regions
(t-DMR). However, 12 age-modified CpG sites were an-
notated to cancer-specific DMR (c-DMR) and 62 CpG
sites to reprogramming-specific DMRs (r-DMR) [35].
Based on the regulatory feature group, 15.8% of the
age-modified CpGs were annotated as gene-associated
cell-type specific (n = 8), promoter-associated cell-type
specific (n = 17) and unclassified cell-type specific
(n = 101), Additional file 1. We also evaluated the DNA
methylation levels of age-modified CpG sites in a dataset
of sorted blood leukocytes from male adults [34]. Inter-
estingly, 38% of 794 age-modified CpG sites identified in
this study showed homogeneous DNA methylation in
sorted leukocytes, granulocytes and peripheral blood
mononuclear cells from healthy adults (Figure 1E and
Additional file 1); suggesting that at least these age-
modified CpG sites may not be lineage specific and that
it is unlikely that the detected age effects would be a
A B
93695
age
individual
391029377476
853 age-modified 
CpG sites
805 CpG sites
794 CpG sites
months after birth
C
464 
age-demethylated
CpG sites (58.4%)
330
age-methylated
CpG sites (41.5%)
Filter by SNPs in 
probe sequence
Filter by 
cell-specific
sites
age 3 6 12 24 36 48 60
(n) 9 7 9 10 6 9 10
D E
methylation status in  
sorted adult leukocytes   
# of age 
modified CpG 
sites in children
methylated (in all leukocytes) 58
unmethylated (in all leukocytes) 203
hemymethylated
(in all leukocytes) 
41
M-value difference > 2 
in granulocytes vs. pbmc
59
Figure 1 Descriptive information of age-modified CpG sites. (A) Schema showing the time points analysed, number of samples (n) and the
number of differentially methylated CpGs based on age and individual. (B) Filtering steps on the 853 age-modified CpGs. (C) Chromosomal
distribution of age-modified CpGs in relation to the expected proportions according to the location of all probes in the 450 K assay. (D)
Distribution of age-modified CpG sites within RNA coding regions or intergenic regions in relation to the expected proportions of all probes in
the 450 K assay. (E) Number of age-modified CpG sites that were found homogeneously methylated in seven populations of sorted blood
leukocytes, granulocytes and peripheral blood mononuclear cells (PBMCs) from healthy adults as described in [34]. The list of age-modified CpG
sites with homogeneous methylation in sorted leukocytes is presented in Additional file 1.
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7.4% of all the age-modified CpG sites had a difference
of at least two units in M value between the mono-
nuclear fraction and the granulocyte fraction (Figure 1E),
suggesting that methylation at those age-modified CpG
sites is much variable between mononuclear cells and
granulocytes, and therefore they are more susceptible
to be affected by cell heterogeneity.The genomic distribution of age-modified CpG sites
The chromosomal distribution of the age-modified CpG
sites according to their Bonferroni-corrected P value (pbonf)
is presented in Figure 2A. Genes containing the most sig-
nificant age-modified CpG sites in peripheral blood leuko-
cytes within 5 years after birth are annotated in the figure
(pbonf below 6.5 × 10
−8). The Illumina identifier is presented
for three age-methylated CpG sites without any transcripts
Table 2 Age-methylated regions within 3 to 60 months after birth in blood leukocytes
Gene
symbol
Gene name Function Locus Number
of CpGs
Illumina ID Region
length (bp)
TTC22 Tetratricopeptide repeat
domain 22
Mediate protein-protein
interactions and chaperone
activity
1p32.3 3 cg24550149 454
cg15645660
cg11949335
SPEG SPEG complex locus Myocyte cytoskeletal
development and marker of
differentiated vascular
smooth cells
2q35 3 cg14074251 51,924
cg26530345
cg02557933
SNED1 Sushi, nidogen and EGF-like
domains 1
Membrane-bound signalling
molecule; hormonal regulation
2q37.3 5 cg02532017 34,671
cg07644939
cg25241559
cg19075225
cg17053285
TRIM7 Tripartite motif containing 7 Ubiquitin protein ligase; Initiation
of glycogen synthesis
5q35.3 2 cg17279652 170
cg26600753
DDR1 Discoidin domain receptor
tyrosine kinase 1
Regulation of cell growth,
differentiation and metabolism;
cell communication with
environment
6p21.3 3 cg16215084 238
cg00934322
cg09965419
TNXB Tenascin XB Anti-adhesive effect; matrix
maturation during wound
healing
6p21.3 3 cg19071976 51,088
cg16662408
cg02657865
MAD1L1 MAD1 mitotic arrest
deficient-like 1
Mitotic spindle-assembly
checkpoint; cell cycle control
and tumour suppression
7p22 6 cg13700912 182,950
cg06555468
cg19513987
cg16026522
cg09174162
cg00963171
UPP1 Uridine phosphorylase 1 Phosphorolysis of uridine to
free bases
and ribose-1-phosphate
7p12.3 3 cg14983135 170
cg10317717
cg21484940
ZNF503 Zinc finger protein 503 TF; transcriptional regulation;
neural
precursor cell proliferation
10q22.2 2 cg13997975 553
cg03487027
DGKZ Diacylglycerol kinase, zeta Kinase; regulate diacylglycerol
levels in intracellular signal
transduction
11p11.2 2 cg18908017 3,940
cg09802018
B4GALNT1 Beta-1,4-N-acetyl-galactosaminyl
transferase 1
Biosynthesis of G(M2) and G(D2)
glycosphingolipids
12q13.3 2 cg09932758 1,936
cg25663970
BTBD11 BTB (POZ) domain
containing 11
Transcription cofactor; Protein
heterodimerization activity (?)
12q23.3 3 cg27567561 566
cg13935577
cg01478234
TEPP Testis, prostate and placenta
expressed
Unknown 16q21 2 cg12499872 91
cg00491255
CNTNAP1 Contactin-associated
protein 1
Recruitment and activation of
intracellular signalling pathways
in neurons
17q21 2 cg16308533 39
cg11629889
TBCD Tubulin folding cofactor D Folding of beta-tubulin 17q25.3 2 cg16555866 35,310
cg00663986
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Table 2 Age-methylated regions within 3 to 60 months after birth in blood leukocytes (Continued)
NFIX Nuclear factor I/X CCAAT-binding
transcription factor
Transcription factor (TF) 19p13.3 4 cg06458248 9,812
cg27392771
cg01634146
cg10767662
LRFN1 Leucine-rich repeat and
fibronectin type III domain
containing 1
Promotes neurite outgrowth in
hippocampal neurons.
Regulates and maintain
excitatory synapses
19q13.2 2 cg26910511 100
cg25156118
TMC2 Transmembrane channel-like 2 Ion channel; expression
in the inner ear suggests
that it may be crucial for
normal auditory function
20p13 3 cg12233487 146
cg23648082
cg03243506
CLDN5 Claudin 5 Claudin (physical barrier to
solutes); membrane protein
and tight junctions
22q11.21 2 cg04463638 366
cg14553765
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most significant age-modified CpG at chr. 22:28074071
(cg16331674, pbonf = 8.1 × 10
−11). The majority of the top
significant age-methylated CpG sites were also homoge-
neously methylated in sorted peripheral blood leukocytes
from healthy adults (showed with an asterisk in Figure 2A).
Furthermore, we found that many of the top significant
age-modified CpG sites were embedded into age-modified
regions (see Figure 2A, Tables 2 and 3). Examples of the
time trends for age effects on DNA methylation in methyl-
ated and demethylated sites are presented in Figure 2B.
Overall, the kinetics of the DNA methylation changes over
time differed according to each site. Some CpGs were ini-
tially unmethylated (M value below −1) and became meth-
ylated (M value above 1) while other CpGs had M values
above 1 that further increased over time (Figure 2B).
Since the majority of age-modified CpG sites were associ-
ated to a known transcript (Figure 1D) and their location
can provide insights on their putative biological relevance,
we analysed the genomic distribution of the 794 age-
modified CpG sites according to their proximity to a CpG
island and other genomic regulatory features like DNAse I
hypersensitivity sites (DHSs) and enhancers. The annota-
tion to be inside a CpG island was significantly over-repre-
sented in age-methylated CpG sites (20.9%) compared
to age-demethylated sites (12.9%) (χ2 = 8.44, P = 0.003),
Figure 3A. There were no differences in the distribution of
age-modified CpG sites with regard to CpG island shores
(39.6% vs 33.6%, P = 0.08) or the ‘open sea’ (37.9% vs.
33.6%, P = 0.21) (Figure 3A). Regarding the connection of
age-modified CpG sites with regulatory features, age-
demethylated CpG sites were more frequently found in
DHS (26.7% vs 14.5%, χ2 = 12.4, P = 0.0004) and promoter-
associated regions (29.7% vs 3.3% χ2 = 88.2, P < 0.00001)
than in age-methylated sites (Figure 3B). There were no
differences in the distribution of age-modified CpG siteswithin enhancers or known differentially methylated re-
gions (DMRs, Figure 3B).
Differential TSS relationship between age-methylated and
age-demethylated sites
We then investigated the distribution of age-modified CpG
sites according to their position within the gene structure.
Provided that any given CpG site can be annotated to a
gene in more than one accession number (for instance, in
case of isoforms or anti-sense transcripts), all locations as-
sociated to an age-modified CpG (TSS1500, TSS200,
5′UTR, 1st exon, gene body, 3′UTR and intergenic) were
included in the analysis. We found that age-methylated
CpG sites were over-represented in the gene body com-
pared to age-demethylated CpG sites (52.5% vs 34.9%, χ2 =
39.8, P < 0.0001), and age-demethylated CpG sites were
more frequently annotated within 1,500 bp of the tran-
scriptional start site (TSS) compared to age-methylated
sites (22.4% vs 8.93%, χ2 = 41.3, P < 0.0001), Figure 3C. To
obtain further insights on their relationship with promoter
regions, we calculated the position (upstream or down-
stream) and distance of each site to its nearest TSS. The
distribution binned by the absolute distance revealed that
about half of the age-demethylated CpG sites spanned
within 0 to 5 kilobases (kb) of a TSS compared to age-
methylated CpG sites (51.7% vs 32.1%, χ2 = 30.1, P= 0.0001).
Conversely, age-methylated CpG sites were more fre-
quently annotated from 5 to 50 kb of a TSS (42.1% vs
32.3%, χ2 = 7.0, P = 0.004) and from 50 to 500 kb (27.7% vs
15.9%, χ2 = 11.5, P = 0.0007), Figure 3D. We also found dif-
ferences in the proportions regarding directionality to the
TSS (upstream/downstream): age-demethylated sites were
more frequent within −5 to +5 kb and age-methylated sites
within +5 to +50 kb downstream of the TSS (Figure 3E).
It is still a matter of debate whether age-associated
changes in DNA methylation are biologically relevant.
Table 3 Age-demethylated regions within 3 to 60 months after birth in blood leukocytes
Gene symbol Gene name Function Locus Number
of CpGs
Illumina ID Region
length (bp)
PRDM16 PR domain containing 16 TF; zinc finger transcription
factor (KRAB box)
1p36.23-p33 4 cg17001566 249,737
cg12436196
cg01418153
cg03254465
CITED4 Cbp/p300-interacting
transactivator, with Glu/
Asp-rich carboxy-terminal
domain, 4
Transcriptional co-activator; CBP
and p300 binding; co-activator
of AP2
1p34.2 2 cg08719289 42
cg10705800
ATOH8 Atonal homolog 8 TF, DNA binding, transcriptional
regulation; nuclease
2p11.2 3 cg05318142 13,349
cg08079596
cg05584950
HDAC4 Histone deacetylase 4 Histone deacetylase; reductase;
transcriptional repression when
tethered to a promoter
2q37.3 3 cg05870586 362
cg15058210
cg05903736
CLEC3B C-type lectin domain
family 3, member B
(tetranectin)
Extracellular matrix structural
protein
3p22-p21.3 3 cg02396676 224
cg22505962
cg06117855
B3GALT4 UDP-Gal: betaGlcNAc
beta 1,3-galactosyltransferase,
polypeptide 4
Glycosyltransferase; synthesis of
type 1 carbohydrate chains.
Biosynthesis of ganglioseries
glycolipid.
6p21.3 2 cg17103217 172
cg06362282
NFE2L3 Nuclear factor (erytroid-
derived 2)-like 3
TF; binding of antioxidant
response elements in target
genes.
7p15.2 2 cg14684457 143
cg10536999
CUX1 Cut-like homeobox 1 TF; DNA binding protein.
Regulate gene expression,
morphogenesis, differentiation
and cell cycle progression
7q22.1 3 cg10692693 82
cg05910443
cg03310939
NACC2 NACC family member 2,
BEN and BTB (POZ) domain
containing
Histone deacetylase 9q34.3 2 cg14147151 37,942
cg14126392
BLOC1S2 Biogenesis of lysosomal
organelles complex-1, subunit 2
Dehydrogenase; formation of
lysosome-related organelles
10q24.31 2 cg26610808 5
cg15298486
HCCA2 YY1-associated protein 1 TF 11q22 3 cg01469847 13,771
cg20973931
cg12007048
ADRBK1 Adrenergic, beta, receptor
kinase 1
Phosphorylation of beta-
2-adrenergic receptor
11q13.1 2 cg13924996 100
cg11436362
SHANK2 SH3 and multiple ankyrin
repeat domains 2
Molecular scaffold in the
postsynaptic density
11q13.2 2 cg11155924 68,036
cg27643147
PSTPIP1 Proline-serine-threonine
phosphatase interacting
protein 1
CD2 binding protein. CD2-
triggered T cell activation;
membrane trafficking
regulatory protein
15q24.3 2 cg26227523 1,804
cg21322248
GPRC5C G protein-coupled receptor,
family C, group 5, member C
G-protein coupled receptor;
cellular effects of retinoic acid (?)
17q25 3 cg12776171 157
cg26663490
cg16120833
MGAT5B Mannosyl (alpha-1,6-)-glycoprotein
beta-1,6-N-acetyl
glucosaminyltransferase, isoenzyme B
Synthesis of complex cell
surface N-glycans
17q25.2 2 cg23838005 66
cg05514299
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Table 3 Age-demethylated regions within 3 to 60 months after birth in blood leukocytes (Continued)
ARID3A AT-rich interactive domain
3A (BRIGHT-like)
TF; cell lineage regulation; cell
cycle control; chromatin
structure modification
19p13.3 4 cg12713583 6,988
cg02001279
cg18598117
cg01774027
TEF Thyrotrophic embryonic factor TF 22q13.2 2 cg20534570 419
cg13228442
TSPO Translocator protein (18 kDa) Steroid hormone synthesis 22q13.31 2 cg00343092 722
cg08909806
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nents and molecular functions were related to genes con-
taining age-modified CpG sites (Additional file 3) and if
there were known interactions between the age-modified
loci. Induced network analysis using the combined list of
age-methylated and age-demethylated loci revealed that sev-
eral of these genes were known to interact within protein-
protein complexes or biochemical reactions (Figure 4). The
over-representation analyses were also performed with sepa-
rated lists as an attempt to dichotomize relevant biological
functions that might be specific to age-methylated and age-
demethylated loci, and these results are explained below.
Genes containing age-methylated CpG sites code for
products involved in development, cell adhesion and the
plasma membrane
Gene ontology (GO) analysis revealed that age-methylated
loci were significantly over-represented in the biological
processes of development and morphogenesis of anatom-
ical structures (Figure 5A and Additional file 4). We also
found that genes having age-methylated CpGs were over-
represented in neuronal-related functions (Figure 4A).
The GO annotations of neuron part (GO:0097458, 20
genes), axon part (GO:0033267, seven genes) and neuron
projection (GO:0043005, 17 genes) were the most significant
in the enrichment based on cell components (Additional
file 4). The over-representation of age-methylated loci
within neuronal genes was also supported by the enrich-
ment in the biological processes of transmission of nerve
impulse (GO:0019226, 18 genes) and neural precursor
cell proliferation (GO:0061351, five genes), Figure 5A
and Additional file 4. Another two highly significant
annotations for age-methylated loci included the plasma
membrane (GO:0005886, 62 genes) and cell adhesion
(GO:0007155, 20 genes), Figure 5A.
Age-demethylated sites were enriched in GO categories
of response to diverse stimuli, immune effector processes
and the cytoplasm
Genes containing age-demethylated CpG sites in blood
leukocytes were significantly enriched in the biological
processes of (1) response to diverse stimuli includingmicroorganisms, chemicals and organic substances; (2)
positive regulation of biological process; (3) immune ef-
fector process; and (4) cell communication and signalling,
Figure 5B. Detailed information on the gene ontology
enrichment for age-demethylated loci is presented in
Additional file 5. Furthermore, genes harbouring age-
demethylated sites were significantly enriched in the cellu-
lar components: cytoplasm (GO:00055737, 194 genes),
intracellular-membrane-bound organelles (GO:0043231,
191 genes) and the Golgi apparatus (GO:0044431, 22
genes). Altogether, this indicates that demethylation in
blood leukocytes within 3 to 60 months after birth is mainly
related to the interaction of the cells with the environment
and the development of immune effector responses. As
shown in Figure 5B, we found that age-demethylated CpGs
were enriched in genes of the major histocompatibility pro-
tein complex (MHC, chr. 6p21.3), including type I (HLA-B,
HLA-C) and type II alleles (HLA-DMA, HLA-DPB1) as well
as the MHC class I polypeptide-related sequence A (MICA).
We also found age-demethylated loci in genes encoding
defensins (DEFA4, DEFB132), prostaglandin receptors
(PTGER2, PTGER4), members of the tumour necrosis fac-
tor superfamily (TNFAIP8L1, TNFRSF8, TNFSF14), inter-
leukin 18 binding protein (IL18BP), interferon regulatory
factor 5 (IRF5), leukotriene B4 receptor (LTB4R), the CD2
ligand on T cells (CD58) and pattern recognition receptors
(NOD2). The longitudinal changes in DNA methylation
levels for some CpG sites located in immune genes are
presented in Figure 6. GO analysis also revealed that age-
demethylated CpG sites were enriched in genes from the
PcG protein complex (CBX7, RNF2, KDM2B, JARID2,
PHF1), Figure 5B and Additional file 5.
Age-modified CpG sites spanned over genes encoding
chromatin remodelling factors and transcription factors
Together with the PcG complex, we found age-modified
CpG sites in genes encoding histone modifiers and chroma-
tin remodelling factors. These included the lysine-specific
‘K’ histone demethylases with F box domains (KDM2A and
KDM2B), AT-rich interaction domains containing proteins
(JARID2 and ARID3A), the structure-specific recognition
protein 1 (SSRP1), the SP140 nuclear body protein-like
AB
Figure 2 Chromosomal distribution and DNA methylation trends of the significant age-modified CpG sites. (A) Dot plot showing the
chromosomal distribution of age-methylated CpGs (blue dots) and age-demethylated CpGs (red dots) in relation to the Bonferroni-corrected P value. For
methylated genes: TTC22= tetratricopeptide repeat domain 22; NES= nestin; NGEF= neuronal guanidine nucleotide exchange factor; SNED1 = sushi
nidogen and EGF-like domains 1; FOXI2 = forkhead box I2; LAG3 = lymphocyte activation gene 3; CRYL1 = crystallin lambda 1; TEPP= testis prostate and
placenta expressed; TSC2 = tuberous sclerosis 2; RHBDL3 = rhomboid, veinlet-like 3 (Drosophila); NFIX= nuclear factor I/X; TMC2: transmembrane
channel-like 2; SOX10= SRY-box 10. For demethylated genes: ATOH8 = atonal homolog 8; CLEC3B = C-type lectin domain family 3, member B,
NRG2 = neuregulin 2; PTK7 = protein tyrosine kinase 7; ANKRD2 = ankyrin repeat domain 2; JRKL = JRK-like; NOD2= nucleotide-binding oligomerization
domain containing 2; ARID3A= AT-rich interactive domain 3A; ZMYND8 = zinc finger, MYND-type containing 8; TSPO = translocator protein (18 kDa);
CLDN2 = claudin 2. An asterisk next to the gene symbol indicates that the age-modified CpG site has similar DNA methylation levels in sorted blood
leukocytes of healthy adults. Genes in bold indicate that the annotated CpG site is embedded in an age-modified region. Detailed information on P
values is presented in Additional file 1. (B) Time trends in DNA methylation (M value) for age-methylated sites (blue) and age-demethylated sites (red). M
values above 1 represent that the site is methylated, and M values below −1 represent that the site is demethylated. A value of 0 is proportional to a beta
value of 0.50. Each line represents a CpG site.
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Figure 3 Differences in the genomic distribution of age-modified CpG sites. (A) Frequency of age-modified CpG sites according to the
proximity to a CpG island (CGI). (B) Frequency of age-modified CpG sites according to regulatory annotations. (C) Frequency of age-modified
CpG sites according to the gene location. TSS = transcriptional start site; UTR = untranslated region; age-methylated CpGs mapped to 537 gene
locations and age-demethylated CpGs to 769 gene locations. (D) Frequency of age-modified CpG sites binned by absolute distance to the nearest
TSS. (E) Frequency of age-modified CpG sites according to their location in relation to the nearest TSS (upstream/downstream).
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dependent chromatin remodelling complex (specific of
neuronal progenitors). The known interactions for nine
age-modified loci involved in chromatin remodelling are
presented in Figure 7A. Some of these genes had more
than one CpG site modified by age that followed the same
trends of age-related changes (Figure 7B and Table 3). The
DNA methylation changes over time in six genes anno-
tated as chromatin/DNA binding proteins are presented
in Figure 7C.
In addition, we found longitudinal changes in DNA
methylation in several genes encoding transcription factors(TFs). A table with the annotation of the TF genes har-
bouring age-modified CpG sites is presented in Additional
file 6. As expected, several CpG sites were found in TFs in-
volved in development such as fork head boxes (FOXI2,
FOXK1 and FOXK2), T-boxes (TBX1 and TBX2), ANTP/
HOXL homeoboxes (HOXA10, HOXA3, HOXB6), the
SRY-related HMG box (SOX10), ANTP/NKL homeoboxes
(VENTX, NKX2) and CUT homeoboxes (CUX1). Several
TFs involved in granulocyte differentiation, B-cell im-
munity and cytokine response were found containing
age-modified CpG sites (Additional file 6). These include
the nuclear factor of activated T-cell 4 (NFATC4), the
Figure 4 Induced network analysis for the known protein-protein interactions between the products of genes containing age-modified
CpG sites. Genes harbouring age-modified CpG sites were used as seeds to identify known protein-protein interactions (orange line), connections
in a biochemical reaction (solid and dotted green lines) and genetic regulation (purple line) at high level of confidence. Node colour represents if
the gene is age methylated (blue) or age demethylated (red). The solid arrow in a biochemical reaction (green) indicates protein/substrate
relationship. Non-connected seed nodes are not shown.
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regulator ERG (ERG), the nuclear hormone receptor
RARA and the GATA zinc finger domain TF (GATA2). In-
duced network analysis using the list of genes having age-
modified CpG sites revealed that several of these TF are
known to interact with the proteins encoded by other age-
modified genes as binary protein-protein interactions and/
or biochemical reactions (Figure 4). With few exceptions,
CpG sites that were age methylated in DIPP children were
found methylated in adult blood, and CpG sites that were
age demethylated in DIPP children were found demethy-
lated in adult blood. A comparison of the DNA methylation
levels (M values) between the children in this study and
adult blood leukocytes is presented in Additional file 7.
Discussion
Here we present a prospective analysis on the dynamics of
DNA methylation in peripheral blood leukocytes during
early childhood. Our study includes data on seven time
points (from 3 to 60 months after birth) from the same ten
individuals and reveals that DNA methylation levels are
modified as a function of age in at least 794 CpG sites dis-
tributed in RNA coding genes as well as intergenic regions
(Figure 1D). Several age-modified CpG sites are located
within the same gene and spread in regions from few basepairs to kilobases (Tables 2 and 3). Our findings indicate
that DNA methylation changes related to age may not only
be due to stochastic DNA methylation drift [14,36] but ra-
ther correspond to a programme with functional relevance
in leukocyte biology. We previously described a group of
differentially methylated CpG signatures related to the
lineage of sorted blood leukocytes in healthy adults [34]. In
the present study, we found CpG methylation signatures
that change as a function of age within the first 5 years
after birth, independently of the individual. It is worth not-
ing that some genes associated to chronic inflammatory
diseases (for example, NOD2, PTGER4, IRF5, ADAM33)
contain age-modified CpG sites in blood leukocytes.
Increased DNA methylation is involved in silencing
developmental genes [37]. We found that genes with age-
methylated CpGs are enriched in biological processes re-
lated to embryonic development and cell adhesion, as well
as with the plasma membrane (Figure 5A and Additional
file 4). Among the most important observations from this
study is the differential genomic distribution of age-
methylated CpG sites, which are more frequently located
within 5 to 50 kb from the TSS and over-represented in
gene bodies and intragenic CpG islands (Figure 3). This is
very interesting because intragenic methylation can pre-
dict gene expression levels, it is crucial in regulating
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Figure 5 Gene ontology (GO) categories significantly enriched in genes harbouring age-modified CpG sites. Summary of GO categories
presented in a two-dimensional space derived by applying multidimensional scaling to a pairwise distance matrix of the semantic similarities in
GO terms. (A) Enriched GO categories in age-methylated CpG sites (blue); (B) Enriched GO categories in age-demethylated sites (red); colour
scales represent the Benjamini-Hochberg corrected log P value for the enrichment (log P −2 equals P = 0.01). Circle sizes indicate the number of
genes of each GO term (set size). Detailed information on enriched GO categories, number of age-modified loci per GO term and P values is
presented in Additional file 3 (for age-methylated CpGs) and Additional file 4 (for age-demethylated CpGs). For this visualization approach, highly
similar GO categories are grouped together and cluster representatives are selected based on P values and dispensability scores. Each GO term
receives a coordinate so that more semantically similar GO terms get closer in the plot [58]. To be regarded as significant, any GO term requires
coincidence of at least five genes and a pbh = 0.05.
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represented in genes that guide the formation of junctions
in the motor neurons [39]. We also found that CpG sites
that are age methylated in blood leukocytes are commonlylocated in genes related to neuronal functions. Several of
those (for example, NEGF, SEPT5, PDE2A,) show detect-
able mRNA expression in brain tissues but not in sorted
blood leukocytes (Figure 8A). Besides, some genes related
Figure 6 Longitudinal trends of the DNA methylation levels in six immune genes within 3 to 60 months after birth. DNA methylation
levels are expressed as M value; each dot represents an individual. The dotted lines represent the 95% CI of the regression line; logfc = log fold
change in methylation over time; pbonf = Bonferroni-corrected P value. IRF5 = interferon regulatory factor 5; NOD2 = nucleotide-binding
oligomerization domain containing 2; IL18BP = interleukin 18 binding protein; PTGER4 = prostaglandin E receptor 4; TNFRSF8 = tumour necrosis
factor receptor superfamily, member 8; HLA-B =major histocompatibility complex, class I, B.
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ample, IL17RD) reflecting that in human leukocytes,
differences in DNA methylation are tightly related with
cell differentiation and commitment to lymphoid and
myeloid lineages [40].
On the other hand, demethylation in promoter regions
is known to facilitate gene expression [41]. Previous
studies have shown that age-demethylated sites from
birth to the first 2 years are enriched in immune-related
genes [22]. Our results replicate these findings and also
show that genes harbouring age-demethylated CpGs are
enriched in genes related to the response to diverse
stimuli including endogenous compounds and organic
and chemical substances (Figure 5B and Additional file 5).Interestingly, age-demethylated CpGs were enriched in
genes related to the cytoplasm, the intracellular organelles
and the Golgi apparatus. These findings could in part be
explained by demethylation of class I and class II
MHC molecules as well as by demethylation of at least
five enzymes involved in glycosylation pathways that
are located in the Golgi apparatus (that is, B3GALT4,
GALNT14, ST6GAL2, FUT7 and FUT3). Moreover, we
identified CpG sites in genes encoding histone modifiers
and chromatin remodelling factors that become demethy-
lated in blood leukocytes by increasing age. The impli-
cated molecules have histone demethylase activity
(JARID2, KDM2A and KDM2B) and histone deacetylase
activity (HDAC4, NACC2) (Figure 7). The demethylation
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Figure 7 DNA methylation levels within 3 to 60 months after birth in genes encoding histone modifiers and chromatin remodelers. (A)
Protein interactions among genes related to the chromatin remodelling machinery that contain age-modified CpG sites; protein-protein interaction
(orange line); biochemical reaction (green line); factors encoded by age-demethylated genes (red) and age-methylated genes (blue). (B) Longitudinal
changes in DNA methylation for two CpG sites in the genes encoding for AT-rich interactive domain-containing protein 3A (ARID3A) and the histone
deacetylase 4 (HDAC4); each dot represents an individual. (C) Longitudinal changes in DNA methylation for six genes involved in the chromatin
remodelling; each dot represents an individual. KDM2A= lysine (K)-specific demethylase 2A; CBX7 = chromobox homolog 7; RNF2 = E3 ubiquitin-protein
ligase RING2; SP140L= SP140 nuclear body protein-like; JARID2 = jumonji, AT-rich interactive domain 2; SMARCD3 = SWI/SNF-related, matrix-associated,
actin-dependent regulator of chromatin, subfamily d, member 3.
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the dynamic changes that occur in blood leukocytes dur-
ing this period of life and may facilitate their maturation
towards subpopulations. For instance, global DNA methy-
lation remodelling has been observed in the transition
from naïve to memory T cells [42]. In this sense, age-
modified loci may participate as functional intermediates
in a cascade of events that contribute to leukocytematuration. Connections to the epigenetic machinery are
further suggested by the identification of five age-modified
CpG sites in genes encoding microRNAs: three age-
methylated sites in MIR219-2, MIR183/MIR96 and MIR-
LET7A3/MIRLET7B and two age-demethylated sites in
MIR10A and MIR574 (Additional file 1).
More studies are needed to investigate which mecha-
nisms direct the methylation machinery to these age-
AB
Figure 8 mRNA levels of genes harbouring age-modified CpG sites based on the FANTOM5 consortium data. (A) CAGE-defined TSS
expression profiles for the age-methylated genes NGEF, SEPT5 and PDE2A in purified primary leukocytes and brain tissues. (B) CAGE-defined TSS
expression profiles for the age-demethylated genes PTGER4 and PRDM16 and the age-methylated gene SNED1; mRNA levels are presented in
transcripts per million (TPM, y-axis). Forty-five samples from blood and neuronal lineages as evaluated by the FANTOM5 consortium [43] are
represented in the x-axis. Detailed information on the samples included in this comparison is presented in Additional file 8.
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date the connection between age-demethylated loci and
mRNA expression in blood leukocytes. This study revealed
that age-demethylated CpG sites are more frequently lo-
cated in DHS, in promoters and in close proximity to the
TSS (Figure 3), suggesting that these changes in methyla-
tion may be biologically relevant at the transcriptionallevel. We found significant GO categories related to the
immune system, and using the FANTOM5 data [43], we
observed that some age-demethylated genes are indeed
expressed in peripheral blood leukocytes but not in other
tissues (for example, PTGER4, Figure 8B and Additional
file 8). In agreement with previous studies showing that
age-induced differential methylation may occur without
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DNA methylation changes over time but without detect-
able differences in expression (Figure 8B and Additional
file 8). Further studies are needed to elucidate which pro-
portion of the age-associated changes in DNA methylation
are part of a ‘programme’, how many are stochastic, which
ones contribute to differential gene expression and how
many are tissue independent or tissue specific.
Previous studies have found age-modified CpG sites that
are restricted to certain tissues [45]. However, age-
modified CpG sites have been detected in tissues that
originate from distinct germ layers, suggesting that tissue-
independent changes do occur. For instance, a common
age-modified methylation module has been found in whole
blood and brain tissue [46]; others have described common
age-modified signatures within the whole blood, lung tissue
and cervix [27], and studies in adult women revealed age-
modified CpG sites in the blood that showed concordant
patterns in other non-haematopoietic tissues [7]. Among
the reported epigenetic biomarkers of ageing in adult’s
samples, we validated one age-demethylated CpG site in
FHL2 (cg06320277, pbonf = 8.44 × 10
−6) but did not detect
significant differences for other reported age biomarkers
[11,12], suggesting that age-modified loci may differ be-
tween children and adults. We also found concordance
with 34 age-modified CpG sites that were previously de-
scribed by Alisch et al., in peripheral blood leukocytes in
paediatric populations [20], and 11 differentially methyl-
ated CpG sites described by Martino et al., comparing
mononuclear cells from cord blood and children age 1 year
[22]. Common loci between ours and these studies in-
cluded TSPO, GAL3ST1, BST2, ASB16, MARK2 and the
inner-ear expressed genes OTOS (otospiralin) and TMC2.
These common age-modified loci were identified in studies
conducted in males [23] and females [22].
Provided that we filtered out cell-type-specific CpG sites
from the list of age-modified CpGs and some of the age-
modified CpG sites have been previously detected by using
fractionated and unfractionated blood, it is less likely that
compositional differences in cell counts may have affected
these observations. Additional insights about common,
non-tissue-specific, age-related methylation signatures
were obtained from the identification of 29 CpG sites that
were age modified in this study and also found differen-
tially methylated in the buccal epithelium of twins between
birth and the age of 18 months [21]. These sites mapped to
21 know genes including ARID3A, KLF9, NOD2, PRKCZ,
SOX10, SPEG, TEPP, TRIM7, TTC22 and ZNF710. The
gene ARID3A is very interesting because it was found con-
taining four age-demethylated CpG sites in a region of
6.98 kb. This molecule is expressed in leukocytes of mye-
loid origin and is involved in normal embryogenesis and
haematopoiesis. Observed age effects on the DNA methy-
lation levels of ARID3A within the first 2 years of life havealso been reported in children with a different genetic
background and environmental setting [23], as well as in
males [20]. Furthermore, the identification of age-modified
CpG sites in several genes related to the formation of or-
gans from the three germinal layers (Additional file 4) sug-
gests that for some loci, the peripheral blood leukocytes
remember an age-related programme that is common
across different tissues. The results of this study suggest
the existence of age-modified loci that are not leukocyte
specific but can be detected in blood as a surrogate tissue.
To our knowledge, this is the first time the same individ-
uals have been followed for this number of time points at
this early age rendering 60 samples for analysis. The num-
ber of age-modified CpGs detected in this study (n = 794)
is lower compared to those previously described, reflecting
a very stringent statistical model that calculated the vari-
ation over many time points and included the individual as
covariate. Several factors (gender, lifestyle, environmental
exposures, sequence variants in cis,) may influence the dy-
namics in which a given CpG site is methylated or
demethylated during lifetime. We could not rule out that
environmental differences like season of birth, maternal
smoking, breastfeeding, mode of delivery, infections and/or
vaccinations may have introduced sources of variation
[47,48]. Nevertheless, we included the parameter related to
the individuals in order to attenuate the possible confound-
ing effect coming from the repeated sampling procedure.
We think that in combination with assuming additive (and
close to linear effects), the model applied here reduced the
list of age-modified CpGs to those that have less interindi-
vidual variability, some even previously observed. Assum-
ing an additive model in this sense is probably suboptimal
but reasonably effective to remove very strong individual’s
related effects. It should be mentioned that other analytical
strategies such as mixed effects models, which allows a
random intercept by individual, are suitable for this type of
longitudinal analysis; however, we did not use this ap-
proach in this specific study because mixed models with
such a big number of probes is computationally expensive
and might suffer from the fact that each probe might re-
spond differently from the others.
Another serious limitation of this study is that we mea-
sured DNA methylation in unfractionated blood and did
not have differential cell counts at the time of sampling to
adjust the analysis. In an attempt to remove as much as
possible the confounding effects due to differential cell
composition, we filtered the list of age-modified CpG sites
against those identified as cell-type specific for leukocyte
populations. We are aware that filtering age-modified CpG
sites in children by the locations having differential methy-
lation in sorted leukocytes in adults is suboptimal, but it is
still the best that can be done to date; however, we believe
that not considering the locations showing differential
methylation in adulthood is not detrimental for this
Acevedo et al. Clinical Epigenetics  (2015) 7:34 Page 17 of 20analysis and is still beneficial as it allows focusing on func-
tionally relevant features. On the other hand, using existing
methods for data deconvolution based on the adult cell-
specific methylation profiles is risky as this data might not
be relevant in children samples with a physiologically dif-
ferent cell composition and, hence, it might produce arte-
facts. Further studies are needed to address this point
properly. A larger prospective study on longitudinal
changes in DNA methylation during childhood is now on-
going in our laboratory including both males and females
exposed to different lifestyles.
Conclusions
This study provides a catalogue of 794 age-modified CpG
sites that robustly reflect the changes in DNA methylation
levels that occur in human blood leukocytes within 3 to
60 months after birth. Age-methylated CpG sites are sig-
nificantly over-represented in genes involved in develop-
mental and neuronal-related functions indicating that
DNA methylation might play an important role in regulat-
ing differentiation and leukocyte-specific functions. On the
other hand, genes harbouring age-demethylated sites re-
flect not only the immunological window in childhood but
also suggest that blood leukocytes undergo a programme
that allows their interaction with environmental factors
and genome remodelling. The fact that methylation in sev-
eral genes implicated in the physiopathology of inflamma-
tory diseases is modified during the first years of life opens
new perspectives on the role of environmental exposures
and strategies for primary prevention. Our results provide
valuable information on age-modified loci that can be use-
ful for developing tools to correct for age effects when per-
forming DNA methylation studies in children.
Methods
Study population
Ten healthy girls were selected from the Type 1 Diabetes
Prediction and Prevention Study (DIPP) [49] to conduct a
prospective genome-wide methylation analysis during
childhood. The children were selected based on the avail-
ability of prospective samples, and that all remained
healthy and seronegative for the T1D-associated antibodies
(ICA, IAA, GADA and IA-2A) by 10 years of age. The
DIPP study was launched in 1994 in Finland as a genetic
screening programme for type 1 diabetes (T1D) risk alleles
in newborn infants from the general population. The chil-
dren included in this study were born between March
2000 and November 2002 in Tampere, Finland; all followed
the Finnish vaccination programme and were carriers of
the HLA-DQB1*03:02 allele but lacking DQB1*06:02 allele.
The HLA-DR-DQ genotypes of the children as well as
genotype-associated risk classes [50] are presented together
with demographical characteristics in Table 1. Blood sam-
ples were collected during visits to the study centre at 3, 6,12, 24, 36, 48 and 60 months after birth. Information on
the clinical history of autoimmune diseases and exposures
to diverse environmental factors (infections, diet, domicile,
living habits, vaccinations,) was also collected. This study
was conducted in accordance with the ethical principles
for medical research stated in the Helsinki Declar-
ation. The ethical committee of the Tampere Univer-
sity Hospital (Tampere, Finland) approved this study.
Written informed consent was obtained from the parents
of all the participants.
Blood samples
Blood samples were taken in sodium citrate tubes and
processed within 1 h from venipuncture. Samples were
centrifuged at 1,700 g during 10 min at room temperature.
After plasma collection, the buffy coat layer was removed
to a separate the cryotube and contaminated red blood
cells were lysed using osmotic shock in sterile water. The
buffy coat containing unfractionated leukocytes was then
pelleted by centrifugation, supernatant was removed and
cells were suspended in sterile water and pipetted to a sep-
arate cryotube. Samples were stored at −80°C until DNA
extraction.
DNA extraction and DNA methylation measurements
Genomic DNA from peripheral leukocytes was extracted
from buffy coats using the FlexiGene kit (QIAGEN,
Hilden, Germany, Cat # 51204). DNA samples (n = 70)
were diluted at 100 ng/μl in TE buffer (pH 8.0). The
mean value for the A260/280 coefficient was 1.90 ± 0.05.
DNA samples were diluted at 11 ng/μl, randomized in a
96-well plate and bisulfite treated using the EZ-96 DNA
Methylation™ Kit (ZYMO Research, Irvine, CA, USA,
Cat # D5004) according to the manufacturer’s instruc-
tions. Six DNA samples with 0%, 50% and 100% methy-
lation (two of each) were included as controls (EpiTect
Control DNA, QIAGEN, Cat # 59665 and Cat # 59655).
Nine technical duplicates of the study samples were in-
cluded to evaluate inter-assay correlations. Denatured
bisulfite-treated DNA was amplified, fragmented and
hybridized onto the HumanMethylation450 BeadChip
(Illumina, Cat # WG-314-1003) following manufacturer
instructions at the Bioinformatics and Expression Core
Facility (BEA, Karolinska Institutet, Stockholm, Sweden).
After extension and staining steps, the chips were
scanned using the Illumina iScan (Illumina, San Diego).
The Infinium methylation data are available in the Gene
Expression Omnibus (GEO) database under the acces-
sion number GSE62219.
Quality control and data normalization
Image analysis and signal detection were done using
the Genome Studio Software. The quality control
(QC) included the evaluation of detection P values,
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specificity. The lumi package was then used for pre-
processing and normalization of the data [51]. The QC also
included unsupervised hierarchical clustering and principal
component analysis (PCA) on sample relationships based
on CpG sites. The data was processed exactly as described
previously [34] and QC verified as raw data and also after
normalization by the quantile method. Based on these ana-
lyses, 60 biological samples passed QC and were studied
(Table 1). Methylation levels in the 0%, 50% and 100% con-
trols resulted as expected.
Statistical analysis on differential methylation
DNA methylation levels were log2 transformed to M
values and then statistically evaluated using the limma
package [33]. A single procedure consisting of two steps
was used to infer the association between age and DNA
methylation, which resulted in a unique list of differen-
tially methylated CpG sites. First, a linear model was
used considering the age and the individual (repeated
samples from the same person); the study of the variance
was performed at this step, but no list of differentially
methylated probes was generated. The information on
the variance was then utilized as prior for the second
step of the analysis, which consisted of a moderated
t-test to compare the samples between the earliest and
the latest time points (that is, 3 months vs 60 months
after birth). The magnitude of the change in M values
over time is indicated by the logfc: negative values indi-
cate how much a CpG site decreases in methylation with
age, while positive values indicate how much a CpG site
increases in methylation. The moderated t-statistic is
expressed as the column t. The significance level was set
at P = 0.01 after multiple testing correction according to
the Bonferroni method (pbonf ).
Data filtering of differentially methylated CpG sites
Fifty nine of the age-modified CpG sites had a single nu-
cleotide polymorphism (SNP) annotated within less than
ten base pairs (bp) from the query site and 99 CpG sites
with a SNP annotated within the probe but >10 bp of the
query site. The minor allele frequency (MAF) of each SNP
within the probe sequence was interrogated in the Finnish
population using ENGINES (Entire Genome Interface for
Exploring SNPs) [52], and CpG sites containing a SNP in
the probe with MAF above 0.01 were filtered out (n = 48).
Furthermore, to avoid the confounding effects of CpG sites
that are differentially methylated among leukocyte popula-
tions (cell-type specific), all age-modified CpG sites were
contrasted against a list of 2,228 CpG sites with significant
differential DNA methylation in sorted leukocytes [34] that
serve as cell-type classifiers. Eleven age-modified CpG sites
were found annotated as having significant DNA methyla-
tion differences within sorted leukocytes and thereforeexcluded. Given that all individuals were females, we did
not filter out probes based on cross-hybridization [53].
Genomic distribution and annotation of the features
The distribution of age-modified CpG sites according to
their relation to a CpG island, gene structure or regulatory
functions (DNAse I hypersensitivity site, promoter, enhan-
cer or known DMR) was calculated based on the UCSC
Genome Browser annotations provided by Illumina. To cal-
culate statistics on the location of age-modified CpG sites
(TSS1500, TSS200, 5′UTR, 1st exon, gene body, 3′UTR
and intergenic), we included all the annotations connected
to a site. The distance of any given CpG site to the nearest
TSS was calculated by PeakAnalyzer [54]. The absolute dis-
tance and position in relation to single nearest TSS within
1,000 kb was calculated by the Genomic Regions Enrich-
ment of Annotations Tool [55]. The comparisons on the
frequency of age-modified CpG sites (age-methylated vs
age-demethylated) according to their relation to CpG
islands, gene structure or regulatory features (present: yes/
no) were performed by using χ2 and Fisher’s exact test. A
P < 0.05 was considered statistically significant.
Enrichment analyses
Gene ontology analyses were conducted using the DAVID
Bioinformatic Resource tool (v 6.7), ConsensusPathDB [56]
and WebGesalt (WEB-based GEne SeT AnaLysis Toolkit)
[57]. Enrichment significance was determined using the
hypergeometric distribution and considered significant if at
least five genes of the input list coincide with the gene set of
a given gene ontology (GO) category, with a nominal
P value <0.01 and Benjamini-Hochberg P value <0.05 (pbh).
Visualization of enriched gene ontology terms was done by
REVIGO based on semantic similarity-based scatterplots
[58]. Annotations on gene families were obtained from
PANTHER [59]. Induced network analyses were conducted
by ConsensusPathDB to visualize known interactions be-
tween the protein products of the genes harbouring age-
modified loci [56].
Additional files
Additional file 1: A catalogue of the age-modified CpG sites identified
in this study.
Additional file 2: Gene families containing age-modified CpG sites.
Additional file 3: Gene ontology (GO) analysis using the combined
list of genes containing age-methylated and age-demethylated CpG
sites.
Additional file 4: Gene ontology (GO) categories significantly
enriched in genes containing age-methylated sites.
Additional file 5: Gene ontology (GO) categories significantly
enriched in genes containing age-demethylated sites.
Additional file 6: Transcription factor genes harbouring age-
modified CpG sites within 3 to 60 months after birth in blood
leukocytes.
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located on transcription factors and chromatin binding proteins.
The histogram represents the M value: blue (methylated) and red
(demethylated). A comparison with adult blood (WB) and sorted
leukocytes as described by [34] is included for comparative purposes.
PBMC = peripheral blood mononuclear cells. Each individual girl is
represented by a column from 3 months (left) to 60 months (right).
Additional file 8: Gene expression levels for five genes containing
age-associated CpG sites across 43 tissues from the FANTOM5
project [43].
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